Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn`s Disease


A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn`s Disease




The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn`s disease.

Study Status: Recruiting


Condition Intervention Phase
Crohn`s Disease Drug: CP-690,550
Drug: CP-690,550
Phase 2

Verified by Pfizer October, 2013

Sponsored by: Pfizer
Information provided by: Pfizer identifier: NCT01470599

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Canada
Toronto, Ontario M5J 2T3

Pfizer Call Center., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site